Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

11.33
-0.8400-6.90%
Post-market: 11.330.00000.00%16:10 EDT
Volume:1.90M
Turnover:21.89M
Market Cap:866.96M
PE:-7.87
High:12.05
Open:12.05
Low:11.20
Close:12.17
52wk High:14.00
52wk Low:4.35
Shares:76.52M
Float Shares:60.06M
Volume Ratio:2.62
T/O Rate:3.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4390
EPS(LYR):-0.7210
ROE:-81.84%
ROA:-28.64%
PB:6.87
PE(LYR):-15.71

Loading ...

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 Aurora Trial Evaluating Aglatimagene Besadenovec (can-2409) in Advanced Non-small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

THOMSON REUTERS
·
Jun 30

Candel Therapeutics Names Mark Sims Chief Commercial Officer

Reuters
·
Jun 25

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

THOMSON REUTERS
·
Jun 25

Candel Therapeutics Stockholders Approve Directors and Auditor

TIPRANKS
·
Jun 25

Candel Therapeutics Shareholders Elected Four Class II Directors at Annual Meeting

Reuters
·
Jun 25

Candel Therapeutics Updates Employment Agreement with Chief Financial Officer

TIPRANKS
·
Jun 17

Candel Therapeutics CFO Schoch employment agreement keeps base salary at $468,600, bonus target 40%

Reuters
·
Jun 17

Analyst Reiterates Buy Rating on Strengthened Phase 3 Data for Aglatimagene Besadenovec, Maintains $23 Price Target

TIPRANKS
·
Jun 03

Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene

TIPRANKS
·
Jun 02

Candel Therapeutics says Phase 3 trial shows 30% disease-free survival gain for CAN-2409 in localized prostate cancer

Reuters
·
Jun 02

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

GlobeNewswire
·
Jun 02

Candel Therapeutics grants inducement stock options for 63,000 shares at $8.3 each

Reuters
·
Jun 02

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 02

Bank of America Securities Remains a Hold on Candel Therapeutics (CADL)

TIPRANKS
·
Jun 01

Candel Therapeutics price target raised to $9 from $7 at BofA

TIPRANKS
·
May 19

Candel Therapeutics Highlights Phase 3 Prostate Cancer Data

TIPRANKS
·
May 16

Candel says CAN-2409 cuts prostate cancer recurrence risk 39% in Phase 3 follow-up

Reuters
·
May 16

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients From Phase 3 Trial of Aglatimagene Besadenovec (Can-2409) in Localized Prostate Cancer Under Prolonged Follow-up at Aua 2026 Annual Meeting

THOMSON REUTERS
·
May 16

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

GlobeNewswire
·
May 16

Canaccord Genuity Reaffirms Their Buy Rating on Candel Therapeutics (CADL)

TIPRANKS
·
May 15